The Covid vaccine developed by the US company Moderna, one of those that have reached phase 3 of the trial, produces a good immune response in the elderly and the side effects are 'mostly mild or moderate'.
This is confirmed by the data from the phase 1 trial, published in the New England Journal of Medicine, according to which the immune response is similar to that achieved in adults.
The study involved 40 people over 56 who were given two doses about a month apart.
"The antibody response appears similar to that already documented in those who received the vaccine between 18 and 55 years - reads the article - and is higher than the average of a control group of people who donated plasma from convalescents".
According to the study, side effects from the vaccine are 'mostly mild or moderate', with headache, fatigue and pain at the injection site being the most frequent.
The vaccine is one of those in the 'lead group' among those under study, at the last phase of the experimentation along with six others according to the monitoring of the ISS updated to 14 September.
In theory, but experts are skeptical, Russia has already approved one, to which another could soon be added.
According to the RIa news agency, in fact, the one produced by the Siberian laboratory Vector would have concluded the phase 3 experimentation, and would therefore be close to approval.